{
  "schemaVersion": 2,
  "eyebrow": "Rheumatology & Nephrology",
  "title": "Gout Flare Treatment in CKD",
  "summary": "Treat acute gout promptly while excluding septic arthritis and avoiding renal and cardiorenal toxicity. In chronic kidney disease, select colchicine cautiously, favor targeted or systemic glucocorticoids when appropriate, reserve IL-1 blockade for refractory contraindicated cases, and continue long-term urate control.",
  "seoDescription": "Point-of-care approach to acute gout flares in chronic kidney disease: aspiration, renal-safe anti-inflammatory selection, dosing, escalation, and urate management.",
  "clinicalQuestion": "How should clinicians treat an acute gout flare in patients with chronic kidney disease while limiting drug toxicity?",
  "specialty": "Rheumatology",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "acute gout flare",
    "chronic kidney disease",
    "colchicine",
    "glucocorticoids",
    "intra-articular steroid",
    "anakinra",
    "urate-lowering therapy"
  ],
  "keyTakeaways": [
    "Treat suspected gout flares early, but aspirate a new, atypical, or potentially infected joint for crystal analysis and bacterial culture before intra-articular glucocorticoid injection. [17][18]",
    "In CKD, NSAIDs are relatively contraindicated and often avoided; glucocorticoids are commonly the most practical anti-inflammatory option, especially when a single joint can be injected. [13][17][18]",
    "Use the FDA acute-flare colchicine regimen of 1.2 mg followed by 0.6 mg 1 hour later only with CKD-aware dose adjustment and interaction review; dose adjustment should be considered in CKD G5. [12]",
    "Use anakinra off-label when colchicine, NSAIDs, and glucocorticoids are contraindicated, intolerable, or ineffective; evidence in advanced CKD remains limited. [2][17]",
    "For recurrent disease control, allopurinol remains preferred first-line urate-lowering therapy in CKD stage 3 or higher; start low, titrate by serial serum urate, and maintain serum urate below 6 mg/dL. [14][24]"
  ],
  "sections": [
    {
      "id": "first-encounter-triage",
      "eyebrow": "Immediate decisions",
      "heading": "Exclude joint infection before treating presumed gout",
      "intro": "CKD changes drug selection, not the need to evaluate a potentially septic joint.",
      "paragraphs": [
        "For a first monoarthritis, atypical site or pattern, fever, marked systemic illness, immunosuppression, or concern for infection, perform arthrocentesis before injecting glucocorticoid. Send synovial fluid for crystal examination and bacterial culture; a prior history of gout does not remove the need to assess septic arthritis. [16][18]",
        "Once gout is the working diagnosis, initiate anti-inflammatory treatment early after symptom onset; earlier therapy is associated with more rapid flare control. Use local ice as an adjunct, and give patients with recurrent, well-characterized flares a prearranged early-treatment plan. [12][17]",
        "Document CKD stage or current kidney function, heart-failure status, peptic-ulcer history, diabetes control, current colchicine exposure, and concomitant medications before selecting therapy. CKD frequently coexists with contraindications to NSAIDs and can limit colchicine use through reduced clearance and drug interactions. [2][13][17]"
      ],
      "bullets": [
        "If aspiration is feasible in an involved large joint, obtain fluid before intra-articular injection and send bacterial culture. [18]",
        "Avoid reflex opioid escalation when local injection or a short systemic anti-inflammatory course can control crystal inflammation; conventional gout therapies are intended to rapidly suppress pain and synovitis. [12][17]",
        "In decompensated heart failure, avoid NSAIDs and weigh systemic glucocorticoid fluid-retention risk; intra-articular therapy is attractive for accessible monoarticular disease. [6][17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Initial treatment branch for an acute gout flare in CKD. [12][13][17][18]",
        "columns": [
          "Clinical branch",
          "Next action",
          "Treatment implication"
        ],
        "rows": [
          [
            "New or atypical hot swollen joint; infection cannot be excluded",
            "Aspirate; examine for crystals and send bacterial culture before injection. [18]",
            "Do not treat presumed gout with intra-articular glucocorticoid before excluding joint infection. [18]"
          ],
          [
            "Accessible single-joint flare without unresolved infection concern",
            "Use local therapy when aspiration/injection expertise is available. [17][18]",
            "Intra-articular triamcinolone 20-40 mg was used in a CKD cohort and had similar symptom outcomes to oral prednisone. [1][8]"
          ],
          [
            "Polyarticular flare or injection not feasible",
            "Select systemic colchicine or glucocorticoid based on kidney function, interactions, and cardiorenal comorbidity. [12][17]",
            "Avoid NSAIDs when renal or cardiorenal risk is unacceptable. [13][17][18]"
          ],
          [
            "Standard agents contraindicated, ineffective, or intolerable",
            "Consider rheumatology-guided IL-1 inhibition. [17]",
            "Anakinra is an off-label U.S. option; advanced-CKD evidence remains limited. [2][17]"
          ]
        ]
      }
    },
    {
      "id": "anti-inflammatory-selection",
      "eyebrow": "Drug selection",
      "heading": "Choose therapy by joint distribution, CKD severity, and cardiorenal risk",
      "intro": "No single anti-inflammatory regimen is optimal for every CKD phenotype.",
      "paragraphs": [
        "NSAIDs are generally a poor default in CKD because they are associated with interstitial nephritis, analgesic nephropathy, hypertension, and higher kidney-failure risk with indiscriminate chronic use. In acute gout, use only if renal and hemodynamic risk is acceptable and under careful supervision; CKD-focused reviews characterize NSAIDs as relatively contraindicated or contraindicated for flare treatment and prophylaxis. [12][17][18]",
        "For monoarticular or oligoarticular disease, aspiration followed by intra-articular glucocorticoid minimizes systemic exposure. In a retrospective CKD cohort with single-joint gout, triamcinolone 20-40 mg intra-articularly and oral prednisone 0.1-0.3 mg/kg/day produced similar relief and time to resolution; this was not a randomized superiority comparison. [1][8]",
        "For polyarticular disease or when injection is impractical, systemic glucocorticoids are a mainstay in CKD. In patients with concomitant congestive heart failure, consider the tradeoff between systemic glucocorticoid exposure and volume risk; a CKD review identifies dexamethasone as an alternative with lower mineralocorticoid potency when systemic treatment is needed. [17][18]"
      ],
      "bullets": [
        "Prefer intra-articular glucocorticoid when one or a few accessible joints are involved and infection has been evaluated. [17][18]",
        "Use systemic glucocorticoid when disease distribution makes local treatment inadequate; monitor the comorbidities that determine glucocorticoid toxicity, particularly heart failure and diabetes. [6][17]",
        "Avoid NSAIDs in severe heart failure, peptic-ulcer disease, or CKD when renal risk outweighs benefit. [13][18]"
      ],
      "subsections": [
        {
          "heading": "Colchicine in CKD",
          "paragraphs": [
            "When colchicine is selected, administer it early. The FDA-approved acute regimen highlighted in KDIGO is 1.2 mg immediately followed by 0.6 mg 1 hour later, followed by ongoing anti-inflammatory therapy until flare resolution; consider dose adjustment in CKD G5. [12]",
            "Do not assume standard colchicine dosing is safe across CKD stages. Renal-function–stratified flare efficacy data are lacking, and pharmacokinetic studies indicate reduced colchicine clearance with kidney impairment. Review concomitant medications and monitor for toxicity; reported surveillance targets include myalgia, weakness, leukopenia, and elevated creatine kinase or aminotransferases. [2][18]",
            "If the patient is already receiving colchicine prophylaxis, avoid automatically using additional colchicine for the acute flare; a CKD management review instead favored local injection or dexamethasone in a patient with CKD and heart failure already taking prophylactic colchicine. [17]"
          ],
          "bullets": [
            "Use renal-function-aware dosing rather than repeating the standard acute regimen in advanced CKD. [2][12]",
            "Reassess colchicine suitability when CKD coexists with heart failure or when therapeutic-dose colchicine is limited by toxicity risk. [6][17]"
          ]
        },
        {
          "heading": "When to use IL-1 inhibition",
          "paragraphs": [
            "Consider IL-1 inhibition only after conventional options are contraindicated, not tolerated, or unsuccessful. Anakinra is occasionally used off-label in the United States for gout flares in patients with multiple comorbidities that preclude colchicine, NSAIDs, or glucocorticoids. [17]",
            "Do not present IL-1 blockade as equivalent first-line CKD therapy: randomized gout-flare studies have not reported colchicine outcomes stratified by renal function, and CKD-specific evidence for gout therapies remains limited. [2] Anakinra has been reported to suppress gout synovitis in patients unable to use standard agents, including those with acute heart failure, but that evidence includes small observational experience. [5][6]"
          ],
          "bullets": [
            "Use rheumatology input for off-label anakinra selection when standard anti-inflammatory classes are exhausted. [17]",
            "Reserve IL-1 inhibition for high-comorbidity or refractory presentations rather than uncomplicated flares responsive to injection, colchicine, or systemic glucocorticoid. [5][17]"
          ]
        }
      ],
      "table": {
        "caption": "Anti-inflammatory options for gout flares in CKD. [1][2][8][12][13][17][18]",
        "columns": [
          "Option",
          "Best-use phenotype",
          "CKD-specific limitation or action"
        ],
        "rows": [
          [
            "Intra-articular triamcinolone",
            "Single accessible joint after aspiration when indicated. [17][18]",
            "Triamcinolone 20-40 mg was used in a retrospective CKD cohort; symptom outcomes were similar to oral prednisone. [1][8]"
          ],
          [
            "Systemic glucocorticoid",
            "Polyarticular disease or when local injection is not feasible. [17][18]",
            "A mainstay option in CKD; in heart failure, minimize systemic mineralocorticoid burden when possible. [17][18]"
          ],
          [
            "Colchicine",
            "Early flare treatment when renal function and medication profile permit. [12]",
            "FDA acute regimen: 1.2 mg, then 0.6 mg 1 hour later; consider adjustment in CKD G5 and monitor for toxicity. [12][18]"
          ],
          [
            "NSAID",
            "Selected patients only when renal and cardiovascular risks are acceptable. [12]",
            "Relatively contraindicated in CKD and often avoided because of nephrotoxicity and hemodynamic risk. [12][17][18]"
          ],
          [
            "Anakinra",
            "Contraindication, intolerance, or failure of standard therapies. [17]",
            "Off-label in the United States; CKD-specific evidence is limited. [2][17]"
          ]
        ]
      }
    },
    {
      "id": "after-the-flare",
      "eyebrow": "Prevent recurrence",
      "heading": "Do not let CKD prevent treat-to-target urate lowering",
      "intro": "Flare control and crystal depletion require separate treatment plans.",
      "paragraphs": [
        "Start or optimize urate-lowering therapy for tophaceous gout, radiographic gout damage, or frequent flares. After a first flare, conditionally consider urate lowering when CKD stage 3 or higher, serum urate above 9 mg/dL, or urolithiasis is present; otherwise, initiation after an uncomplicated first flare is conditionally discouraged. [14][24]",
        "Use allopurinol as preferred first-line urate-lowering therapy, including in moderate-to-severe CKD. Start at 100 mg/day or lower in CKD, then titrate using serial serum urate measurements to maintain serum urate below 6 mg/dL rather than accepting a fixed dose. Evidence supports dose escalation, including doses above 300 mg/day, in many patients with stage 3 CKD when titrated to target. [14][21][24]",
        "Before allopurinol in patients of Han Chinese, Korean, Thai, or African American ancestry, obtain HLA-B*58:01 testing; ACR conditionally recommends against routine testing in other racial or ethnic groups. This result changes agent selection and counseling because the testing strategy is intended to reduce allopurinol hypersensitivity risk in higher-prevalence populations. [14]"
      ],
      "bullets": [
        "Begin anti-inflammatory prophylaxis when initiating or titrating urate-lowering therapy and continue for at least 3-6 months; extend it if flares persist. [14][24]",
        "Use colchicine, an NSAID, or prednisone/prednisolone as prophylaxis according to renal function and comorbidity; CKD often makes colchicine dosing and NSAID selection more restrictive. [2][14]",
        "Continue serial serum urate-guided titration rather than withholding escalation solely because the patient has CKD. [19][21][24]"
      ],
      "subsections": [
        {
          "heading": "Febuxostat when allopurinol cannot be used",
          "paragraphs": [
            "Febuxostat is an alternative xanthine oxidase inhibitor when allopurinol is not tolerated or fails to achieve target despite appropriate titration. ACR recommends a low starting dose of 40 mg/day or less and serum-urate–guided titration to below 6 mg/dL. [24]",
            "Discuss cardiovascular uncertainty explicitly in patients with established cardiovascular disease. Comparative trial evidence has found allopurinol noninferior to febuxostat for flare reduction, including among participants with CKD stage 3, whereas the cardiovascular safety literature remains heterogeneous and debated. [19][22]"
          ],
          "bullets": [
            "Do not use febuxostat initiation as a substitute for flare prophylaxis; flares often increase when serum urate begins to fall. [22][24]",
            "Continue treat-to-target monitoring regardless of whether allopurinol or febuxostat is selected. [19][24]"
          ]
        }
      ],
      "table": {
        "caption": "Long-term urate-lowering decisions after a flare in CKD. [14][19][21][24]",
        "columns": [
          "Decision point",
          "Action",
          "Target or duration"
        ],
        "rows": [
          [
            "Tophi, radiographic gout damage, or frequent flares",
            "Initiate urate-lowering therapy. [24]",
            "Titrate with serial serum urate to <6 mg/dL. [24]"
          ],
          [
            "First flare plus CKD stage 3 or higher, serum urate >9 mg/dL, or urolithiasis",
            "Conditionally consider urate-lowering therapy. [14]",
            "Use shared decision-making regarding recurrence prevention. [14]"
          ],
          [
            "Allopurinol initiation",
            "Start at ≤100 mg/day and lower in CKD; titrate to serum urate target. [24]",
            "Do not default to a fixed renal-limited maintenance dose. [21][24]"
          ],
          [
            "Starting or titrating urate-lowering therapy",
            "Provide anti-inflammatory prophylaxis. [14][24]",
            "Continue at least 3-6 months; extend if flares continue. [14]"
          ]
        ]
      }
    },
    {
      "id": "monitoring-and-escalation",
      "eyebrow": "Follow-up",
      "heading": "Monitor toxicity, response, and reasons for treatment failure",
      "intro": "Persistent flares require reassessment of diagnosis, exposure, and urate control.",
      "paragraphs": [
        "Reassess the flare if pain, swelling, or function fails to improve after the selected intervention. Reconsider septic arthritis, calcium pyrophosphate crystal arthritis, inadequate local coverage in polyarticular disease, or an alternative inflammatory arthritis; crystal arthropathies and septic arthritis remain key differentials for inflammatory monoarthritis. [16][18]",
        "For colchicine exposure in CKD, actively query muscle pain and weakness and review blood counts, creatine kinase, and aminotransferases when toxicity is suspected. This monitoring is particularly important because CKD reduces colchicine clearance and therapeutic-dose use may be constrained in patients with overlapping heart failure or advanced kidney disease. [2][6][18]",
        "At each urate-lowering follow-up, obtain serum urate and adjust dose toward below 6 mg/dL. Failure to reach target should prompt assessment of adherence, dose escalation capacity, treatment tolerance, and the need to switch from allopurinol to febuxostat rather than accepting persistent hyperuricemia and recurrent inflammation. [19][21][24]"
      ],
      "bullets": [
        "Escalate to aspiration and culture if the clinical course is inconsistent with a typical flare or infection becomes a concern. [16][18]",
        "Seek rheumatology support for recurrent flares despite target-directed therapy, diagnostic uncertainty, tophaceous disease, or consideration of off-label IL-1 inhibition. [17][24]",
        "Continue prophylaxis beyond 3-6 months when flares persist during urate lowering. [14]"
      ],
      "subsections": [],
      "table": {
        "caption": "Response-based follow-up after gout flare treatment in CKD. [2][14][16][18][24]",
        "columns": [
          "Finding",
          "Interpretation",
          "Next step"
        ],
        "rows": [
          [
            "Atypical course, fever, or unresolved concern for infection",
            "Gout may not be the sole diagnosis. [16][18]",
            "Perform or repeat arthrocentesis with bacterial culture and crystal analysis. [18]"
          ],
          [
            "Myalgia, weakness, cytopenia, or suspected biochemical toxicity during colchicine exposure",
            "Possible colchicine toxicity, with increased concern in CKD. [2][18]",
            "Review colchicine exposure and interacting medications; assess creatine kinase, blood counts, and aminotransferases. [18]"
          ],
          [
            "Flares continue after urate-lowering therapy begins",
            "Mobilization flares or insufficient prophylaxis may be present. [14][22]",
            "Continue or extend prophylaxis and titrate urate lowering by serial serum urate. [14][24]"
          ],
          [
            "Serum urate remains ≥6 mg/dL",
            "Crystal-depleting treatment target has not been reached. [24]",
            "Assess adherence and tolerance, then titrate therapy or select an alternative xanthine oxidase inhibitor. [19][21][24]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure | Annals of the Rheumatic Diseases",
      "detail": "ard.bmj.com",
      "url": "https://ard.bmj.com/content/73/Suppl_2/774.2",
      "authors": "ard.bmj.com",
      "host": "ard.bmj.com"
    },
    {
      "number": 2,
      "title": "Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41584-021-00657-4",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 3,
      "title": "Gout | Nature Reviews Disease Primers",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41572-019-0115-y",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 4,
      "title": "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-74154-5",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 5,
      "title": "Innate immunity: current understandings and future perspectives | Signal Transduction and Targeted Therapy",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-026-02920-0",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 6,
      "title": "Anakinra Could Be a Glucocorticoid-sparing Alternative for Colchicine-intolerant/refractory Gout Flare in Acute Heart Failure; Case Series - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916420312392",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 7,
      "title": "Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1297319X18300587",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 8,
      "title": "SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0003496724621345",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 9,
      "title": "Controversies and practical management of patients with gout and chronic kidney disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0085253824004733",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 10,
      "title": "ePosters - Case Reports : Indian Journal of Rheumatology - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ijru/fulltext/2023/18002/eposters___case_reports.3.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 11,
      "title": "Gout: diagnosis and management",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng219/evidence/h-colchicine-nsaids-corticosteroids-and-il1-inhibitors-for-the-prevention-of-gout-flares-during-the-initiation-or-titration-of-uratelowering-therapy-pdf-11080521333",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 12,
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org"
    },
    {
      "number": 13,
      "title": "[PDF] Gout: diagnosis and management - NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng219/evidence/d-pharmacological-and-nonpharmacological-interventions-for-managing-gout-flares-pdf-11080521329",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 14,
      "title": "Press Release: Gout Management Guideline | American College of Rheumatology",
      "detail": "rheumatology.org",
      "url": "https://rheumatology.org/press-releases/acr-releases-gout-management-guideline-with-emphasis-on-treat-to-target-strategy-for-urate-lowering-therapy",
      "authors": "rheumatology.org",
      "host": "rheumatology.org"
    },
    {
      "number": 15,
      "title": "Controversies and practical management of patients with gout and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/S0085-2538(24)00473-3/abstract",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org"
    },
    {
      "number": 16,
      "title": "Management of Immune-Related Adverse Events in Patients ...",
      "detail": "ascopubs.org",
      "url": "https://ascopubs.org/doi/10.1200/JCO.21.01440",
      "authors": "ascopubs.org",
      "host": "ascopubs.org"
    },
    {
      "number": 17,
      "title": "Management of Gout and Hyperuricemia in CKD - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572666",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "How is it different in patients with chronic kidney disease?",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/content/ccjom/77/12/919.full.pdf",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org"
    },
    {
      "number": 19,
      "title": "Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9012032",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Evidence reviews for urate-lowering therapies for the long-term management of gout - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK589579",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6203619",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 22,
      "title": "Febuxostat - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK544239",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Results - Management of Gout - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK356145",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "2020 American College of Rheumatology Guideline for the ... - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10563586",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure | Annals of the Rheumatic Diseases",
      "detail": "ard.bmj.com",
      "url": "https://ard.bmj.com/content/73/Suppl_2/774.2",
      "authors": "ard.bmj.com",
      "host": "ard.bmj.com",
      "snippet": "Title: SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure | Annals of the Rheumatic Diseases\nAnnals of the Rheumatic Diseases. * SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of ",
      "score": 0.6557114
    },
    {
      "number": 2,
      "title": "Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41584-021-00657-4",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "## Drugs used for flares and prophylaxis\n\nFor drugs used in the management of gout flares or flare prophylaxis when starting ULT (namely NSAIDs, colchicine, corticosteroids and IL-1 inhibitors), the efficacy outcomes of interest are resolution or prevention of gout flares, respectively. For this G-C",
      "score": 0.8245895
    },
    {
      "number": 3,
      "title": "Gout | Nature Reviews Disease Primers",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41572-019-0115-y",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition. Gout typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb. Elevated serum urate level (hyperuricaemia) is the major risk factor for MSU crystal deposition and ",
      "score": 0.7309246
    },
    {
      "number": 4,
      "title": "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-74154-5",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Recent clinical trials have demonstrated that effective XOI urate-lowering treatment (ULT) to target eventually reduces gout flare burden and synovitis between 1 and 2 years therapy1632158-5\n                  \n                 (2018).\"),17.\"),18.\"). Importantly, flares decrease in this time frame, d",
      "score": 0.53079647
    },
    {
      "number": 5,
      "title": "Innate immunity: current understandings and future perspectives | Signal Transduction and Targeted Therapy",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41392-026-02920-0",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "In contrast, anakinra is a recombinant human IL-1 receptor antagonist that competitively binds IL-1RI, thereby blocking both IL-1α and IL-1β signaling.437.\") It is approved for rheumatoid arthritis and CAPS. It also rapidly suppresses synovial inflammation to alleviate pain and swelling in gout, par",
      "score": 0.35441124
    },
    {
      "number": 6,
      "title": "Anakinra Could Be a Glucocorticoid-sparing Alternative for Colchicine-intolerant/refractory Gout Flare in Acute Heart Failure; Case Series - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1071916420312392",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Anakinra Could Be a Glucocorticoid-sparing Alternative for Colchicine-intolerant/refractory Gout Flare in Acute Heart Failure; Case Series - ScienceDirect\n## Journal of Cardiac Failure. # 283 Anakinra Could Be a Glucocorticoid-sparing Alternative for Colchicine-intolerant/refractory Gout Flar",
      "score": 0.72231215
    },
    {
      "number": 7,
      "title": "Effectiveness and safety of anakinra in gout patients with stage 4–5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S1297319X18300587",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Arthritis Res Ther\n\n### Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial: rilonacept for gout flare prevention\n\n### Arthritis Rheum\n\n### Canakinumab relieve",
      "score": 0.57780564
    },
    {
      "number": 8,
      "title": "SAT0502 Comparison between Oral or Intra-Articular Corticoids in the Management of Acute Gout Flare in Patients with Chronic Renal Failure",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0003496724621345",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Methods\n\nClinical charts of patients with chronic renal failure with a single joint flare of gout were reviewed. Only patients treated with glucorticoids (oral or intra articular) and who did not receive NSAIDs nor colchicine was included. Epidemiologic variables were analyzed and the effectiven",
      "score": 0.56258565
    },
    {
      "number": 9,
      "title": "Controversies and practical management of patients with gout and chronic kidney disease - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0085253824004733",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Controversies and practical management of patients with gout and chronic kidney disease - ScienceDirect\n# Mini Review Controversies and practical management of patients with gout and chronic kidney disease. As many as one-third of all patients with chronic kidney disease have a history of gou",
      "score": 0.53925073
    },
    {
      "number": 10,
      "title": "ePosters - Case Reports : Indian Journal of Rheumatology - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ijru/fulltext/2023/18002/eposters___case_reports.3.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "responsible for infrequent occurrence of amyloidosis, as it directly targets the IL-1β mediated neutrophil activation. Our patient had never been exposed to colchicine. The agents used to treat gout with amyloidosis in case reports are colchicine, steroids, canakinumab, anakinra, azathioprine, tocil",
      "score": 0.25796875
    },
    {
      "number": 11,
      "title": "Gout: diagnosis and management",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng219/evidence/h-colchicine-nsaids-corticosteroids-and-il1-inhibitors-for-the-prevention-of-gout-flares-during-the-initiation-or-titration-of-uratelowering-therapy-pdf-11080521333",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "people with gout and chronic kidney disease), what is the clinical and cost effectiveness of colchicine, NSAIDs, corticosteroids and IL-1 inhibitors for the prevention of gout flares during the initiation or titration of urate-lowering therapy? The literature searches for this review are detailed be",
      "score": 0.8825193
    },
    {
      "number": 12,
      "title": "KDIGO 2024 Clinical Practice Guideline for the Evaluation and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/%20S0085-2538%2823%2900766-4/fulltext",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org",
      "snippet": "The American College of Rheumatology recommended that colchicine, NSAIDs, or glucocorticoids are preferred first-line therapies for acute gout treatment based on demonstrated high levels of evidence for efficacy, low cost, and tolerability.60700766-4/fulltext#bibliography-surfeit) Administration ear",
      "score": 0.85797083
    },
    {
      "number": 13,
      "title": "[PDF] Gout: diagnosis and management - NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ng219/evidence/d-pharmacological-and-nonpharmacological-interventions-for-managing-gout-flares-pdf-11080521329",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "often overnight. Most flares present to and are managed in primary care. Treatment of gout flares aims to provide rapid relief from joint pain and inflammation. The most commonly used pharmacological interventions to treat flares are non-steroidal anti-inflammatory drugs (NSAIDs), followed by colchi",
      "score": 0.8479807
    },
    {
      "number": 14,
      "title": "Press Release: Gout Management Guideline | American College of Rheumatology",
      "detail": "rheumatology.org",
      "url": "https://rheumatology.org/press-releases/acr-releases-gout-management-guideline-with-emphasis-on-treat-to-target-strategy-for-urate-lowering-therapy",
      "authors": "rheumatology.org",
      "host": "rheumatology.org",
      "snippet": "Indications for starting ULT have been expanded to conditionally consider patients with infrequent gout flares or after their first gout flare if they also have moderate to severe chronic kidney disease (CKD stage ≥ 3), marked hyperuricemia (serum urate > 9 mg/dl) or kidney stones.\n A conditional re",
      "score": 0.6543875
    },
    {
      "number": 15,
      "title": "Controversies and practical management of patients with gout and ...",
      "detail": "www.kidney-international.org",
      "url": "https://www.kidney-international.org/article/S0085-2538(24)00473-3/abstract",
      "authors": "www.kidney-international.org",
      "host": "www.kidney-international.org",
      "snippet": "As many as one-third of all patients with chronic kidney disease have a history of gout, yet <25% of these patients are effectively treated to target serum",
      "score": 0.33607003
    },
    {
      "number": 16,
      "title": "Management of Immune-Related Adverse Events in Patients ...",
      "detail": "ascopubs.org",
      "url": "https://ascopubs.org/doi/10.1200/JCO.21.01440",
      "authors": "ascopubs.org",
      "host": "ascopubs.org",
      "snippet": "anti-SSA, and anti-SSB, have occasionally been found, but most patients tend to be seronegative. Arthritis can occur at any time during treatment with some patients first experiencing symptoms many months after initiation of ICPi therapy.138 Most common differential diagnoses include other causes of",
      "score": 0.32678735
    },
    {
      "number": 17,
      "title": "Management of Gout and Hyperuricemia in CKD - PMC",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572666",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Treatment options for gout flares in the US include colchicine, NSAIDs, glucocorticoids (oral, intra-articular, intramuscular, intravenous), and subcutaneous or intramuscular adrenocorticotropic hormone (ACTH), though there is limited evidence for this latter option. IL-1 antagonism with canakinumab",
      "score": 0.72814995
    },
    {
      "number": 18,
      "title": "How is it different in patients with chronic kidney disease?",
      "detail": "www.ccjm.org",
      "url": "https://www.ccjm.org/content/ccjom/77/12/919.full.pdf",
      "authors": "www.ccjm.org",
      "host": "www.ccjm.org",
      "snippet": "■ ■recommended for OUR PATIENT As for our diabetic patient with an acute gout flare and creatinine clearance rate of 45 mL/ minute, we would recommend: • Aspirating the knee, sending the fluid for bacterial culture, and then treating it with a local glucocorticoid injection • Starting colchicine 0.6",
      "score": 0.6466616
    },
    {
      "number": 19,
      "title": "Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9012032",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "In conclusion, this trial demonstrates that allopurinol is noninferior to febuxostat in flare reduction in participants with gout and that either urate-lowering therapy, when used in a titrate-to-target approach, is highly and nearly uniformly effective in getting participants below serum urate goal",
      "score": 0.91362286
    },
    {
      "number": 20,
      "title": "Evidence reviews for urate-lowering therapies for the long-term management of gout - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK589579",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "events and tophi in a mixed CKD population. There was a clinical harm for febuxostat compared to placebo for frequency of flares in a stage 3 CKD population. One treat-to-target study of Allopurinol 300-600mg compared to Febuxostat 80mg/120mg in a non-CKD population (unclear or mixed line treatment)",
      "score": 0.8820324
    },
    {
      "number": 21,
      "title": "Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities (CARES) trial and associated FDA public safety alert",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6203619",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "lowering, and the gout flares endpoints, were close between dose-titrated allopurinol and febuxostat in CARES (2). Third, more evidence now exists to support allopurinol as a relatively safe urate-lowering drug when risk factors for allopurinol hypersensitivity syndrome are taken into appropriate co",
      "score": 0.8773195
    },
    {
      "number": 22,
      "title": "Febuxostat - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK544239",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "The relationship between febuxostat and cardiovascular disease remains controversial due to challenges in comparing trials and heterogeneous outcomes. A systematic review of 20 randomized controlled trials found reassuring cardiovascular safety outcomes in patients with gout who are treated with feb",
      "score": 0.86024034
    },
    {
      "number": 23,
      "title": "Results - Management of Gout - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK356145",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "We identified one new RCT122 that compared febuxostat and allopurinol in patients with chronic gout (see Table 17). This study randomized 512 Chinese gout patients to febuxostat 40mg, febuxostat 80mg, or allopurinol 300mg for 28 weeks, with flare prophylaxis provided through week 8. No significant c",
      "score": 0.8482825
    },
    {
      "number": 24,
      "title": "2020 American College of Rheumatology Guideline for the ... - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10563586",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Forty-two recommendations (including 16 strong recommendations) were generated. Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with mod",
      "score": 0.8338803
    }
  ],
  "publishedAt": "2026-09-15T21:32:26.919686+00:00",
  "updatedAt": "2026-09-15T21:32:26.919686+00:00",
  "readingMinutes": 6,
  "slug": "gout-flare-treatment-in-ckd"
}